Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization.

Abstract

PURPOSE:

To evaluate retinal sensitivity in the macular area after intravitreal injection of bevacizumab in eyes with myopic choroidal neovascularization (mCNV).

DESIGN:

Prospective interventional case series.

METHODS:

Twenty-two eyes of 21 patients with mCNV were treated with intravitreal injections of bevacizumab. Microperimetry in the macular area was performed with a Micro Perimeter-1 (Nidek, Vigonza, Italy) before, and at 1 month and 6 months after treatment.

RESULTS:

After treatment, visual acuity (VA) and central retinal sensitivity were improved significantly. Mean VA in logarithm of the minimal angle of resolution (logMAR) fashion improved from 0.67 +/- 0.34 to 0.43 +/- 0.33 at 1 month, and to 0.34 +/- 0.26 at 6 months [P < .01, respectively]. Mean retinal sensitivity within the central 10 degree field improved from 4.8 +/- 2.8 decibels (dB) to 6.5 +/- 3.2 dB at 1 month and to 7.4 +/- 4.4 dB at 6 months [P < .01, respectively]. These improvements were more prominent in eyes with juxtafoveal mCNV than in eyes with subfoveal mCNV. With treatment, the mean number of measurement points within the scotomas decreased significantly; the absolute scotoma was reduced substantially in 15 (68%) eyes at 6 months. Unfortunately, the absolute scotoma was significantly enlarged in 1 eye (5%) at 1 month and in 4 eyes (18%) at 6 months. Also at 6 months, chorioretinal atrophy had developed in the macular area in 4 eyes (18%).

CONCLUSIONS:

Although intravitreal injection of bevacizumab improved retinal sensitivity in the macular area, some eyes showed enlargement of the scotoma after this treatment.

• Authors: Yuko Yodoi, Akitaka Tsujikawa, Hideo Nakanishi, Atsushi Otani, Hiroshi Tamura, Yumiko Ojima, Hisako Hayashi, Nagahisa Yoshimura
• Journal: American journal of ophthalmology (Am J Ophthalmol) Vol. 147 Issue 5 Pg. 816-24, 824.e1 (May 2009) ISSN: 1879-1891 [Electronic] United States
• PMID: 19211092 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Coloring Agents
• Vascular Endothelial Growth Factor A
• Bevacizumab
• Indocyanine Green

Topics

• Aged
• Aged, 80 and over
• Angiogenesis Inhibitors (administration & dosage, therapeutic use)
• Antibodies, Monoclonal (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Choroidal Neovascularization (drug therapy, etiology, physiopathology)
• Coloring Agents
• Female
• Fluorescein Angiography
• Humans
• Indocyanine Green
• Injections
• Male
• Middle Aged
• Myopia, Degenerative (complications, drug therapy, physiopathology)
• Prospective Studies
• Retina (physiopathology)
• Scotoma (physiopathology)
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity (physiology)
• Visual Field Tests
• Visual Fields (physiology)
• Vitreous Body